News BioArctic AB

Equities

BIOA B

SE0010323311

Real-time Estimate Cboe Europe Other stock markets 09:04:11 2024-04-26 am EDT			5-day change	1st Jan Change
194.5 ^SEK	+0.41%		0.00%	-26.55%

Apr. 22	Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	DJ
Apr. 15	Nordic Shares Moved Upward Monday; Invisio Led Increases	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 25	AQ
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 24	AQ
Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	Apr. 22	DJ
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	Apr. 20	AQ
Notice of Annual General Meeting in BioArctic AB (publ)	Apr. 19	AQ
BioArctic publishes the Annual Report for 2023	Apr. 18	AQ
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	Apr. 16	AQ
Nordic Shares Moved Upward Monday; Invisio Led Increases	Apr. 15	DJ
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	Apr. 12	DJ
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm	Apr. 10	AQ
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	Mar. 31	AQ
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	Mar. 25	AQ
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit	Mar. 22	DJ
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	Mar. 22	AQ
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease	Mar. 19	AQ
New data on lecanemab presented at the 2024 AD/PD™ congress	Mar. 11	AQ
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
BioArctic's partner Eisai presents updated sales simulation for Leqembi at its annual press conference	Mar. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioArctic AB

Equities

BIOA B

SE0010323311

Summary

Filters